BIOMAT Database Logo BIOMAT Database Logo

Two cycles of MOPP and radiotherapy: effective treatment for stage IIIA and IIIB Hodgkin's disease. 1991

F B Hagemeister, and L M Fuller, and W S Velasquez, and P McLaughlin, and J R Redman, and F Swan, and M A Rodriguez, and L North, and D Dixon, and K Silvermintz
Department of Hematology, University of Texas, M. D. Anderson Cancer Center, Houston.

Two cycles of MOPP (mechlorethamine, vincristine (Oncovin), procarbazine, prednisone) and radiotherapy were used to treat 197 patients with stage III Hodgkin's disease. Prior to 1980, radiotherapy was delivered to the mantle, abdomen and pelvis; thereafter, pelvic irradiation was deleted for patients with stage III1 disease. Complete remission rates for IIIA and IIIB presentations were 91% and 89%. The 10-year freedom from tumor mortality (FTM) rate for all patients was 81%; for IIIA, it was 87% and for IIIB, it was 72%. Results were not significantly affected by gender, age, pathology, or deletion of pelvic radiotherapy. However, a subgroup of 28 patients with a tumor burden that included pelvic disease who also had B symptoms was identified as having a poor prognosis. Their FTM was 43%, compared with 87% for all other patients combined (P = 0.002). Based on this analysis, we conclude that limited chemotherapy in combination with radiation therapy can yield results similar to programs that use more chemotherapy for all patients with IIIA disease and for most patients with stage IIIB. However, patients with tumor burdens which include pelvic disease and B symptoms require a different approach.

UI MeSH Term Description Entries
D008297 Male Males
D008466 Mechlorethamine A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. Chlorethazine,Chlormethine,Mechlorethamine Oxide,Mustine,Nitrogen Mustard,Nitrogen Mustard N-Oxide,Bis(2-chloroethyl)methylamine,Caryolysine,Cloramin,Embichin,Mechlorethamine Hydrochloride,Mechlorethamine Hydrochloride N-Oxide,Mechlorethamine N-Oxide,Methylchlorethamine,Mitomen,Mustargen,NSC-10107,NSC-762,Nitrogranulogen,Nitromin,Hydrochloride N-Oxide, Mechlorethamine,Hydrochloride, Mechlorethamine,Mechlorethamine Hydrochloride N Oxide,Mechlorethamine N Oxide,N-Oxide, Mechlorethamine Hydrochloride,N-Oxide, Nitrogen Mustard,NSC 10107,NSC 762,NSC10107,NSC762,Nitrogen Mustard N Oxide
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma

Related Publications

F B Hagemeister, and L M Fuller, and W S Velasquez, and P McLaughlin, and J R Redman, and F Swan, and M A Rodriguez, and L North, and D Dixon, and K Silvermintz
Treatment of stage IIIA Hodgkin's disease: is radiotherapy alone adequate?
January 1978, International journal of radiation oncology, biology, physics,
F B Hagemeister, and L M Fuller, and W S Velasquez, and P McLaughlin, and J R Redman, and F Swan, and M A Rodriguez, and L North, and D Dixon, and K Silvermintz
Treatment of stage IIIA Hodgkin's disease.
April 1982, Cancer treatment reports,
F B Hagemeister, and L M Fuller, and W S Velasquez, and P McLaughlin, and J R Redman, and F Swan, and M A Rodriguez, and L North, and D Dixon, and K Silvermintz
[Role of radiotherapy in the treatment of stage IIIB Hodgkin's disease in children].
May 1987, Meditsinskaia radiologiia,
F B Hagemeister, and L M Fuller, and W S Velasquez, and P McLaughlin, and J R Redman, and F Swan, and M A Rodriguez, and L North, and D Dixon, and K Silvermintz
Treatment selection for stage IIIA Hodgkin's disease patients.
August 1985, International journal of radiation oncology, biology, physics,
F B Hagemeister, and L M Fuller, and W S Velasquez, and P McLaughlin, and J R Redman, and F Swan, and M A Rodriguez, and L North, and D Dixon, and K Silvermintz
Sequential non-cross-resistant chemotherapy regimens (MOPP and CAVmP) in Hodgkin's disease stage IIIB and IV.
November 1983, Cancer,
F B Hagemeister, and L M Fuller, and W S Velasquez, and P McLaughlin, and J R Redman, and F Swan, and M A Rodriguez, and L North, and D Dixon, and K Silvermintz
The treatment of stage IIIA Hodgkin's disease.
December 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
F B Hagemeister, and L M Fuller, and W S Velasquez, and P McLaughlin, and J R Redman, and F Swan, and M A Rodriguez, and L North, and D Dixon, and K Silvermintz
Mopp chemotherapy in the treatment of stage IV Hodgkin's disease.
January 1985, Haematologica,
F B Hagemeister, and L M Fuller, and W S Velasquez, and P McLaughlin, and J R Redman, and F Swan, and M A Rodriguez, and L North, and D Dixon, and K Silvermintz
Prognostic value of response after three MOPP cycles in Hodgkin's disease--stage III and IV.
March 1987, Blut,
F B Hagemeister, and L M Fuller, and W S Velasquez, and P McLaughlin, and J R Redman, and F Swan, and M A Rodriguez, and L North, and D Dixon, and K Silvermintz
Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
August 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
F B Hagemeister, and L M Fuller, and W S Velasquez, and P McLaughlin, and J R Redman, and F Swan, and M A Rodriguez, and L North, and D Dixon, and K Silvermintz
Radiotherapy or chemotherapy as the initial treatment for stage IIIA Hodgkin's disease (Report no 13).
September 1981, Clinical radiology,
Copied contents to your clipboard!